Skip to main content

Table 1 Association between GP96 overexpression and clinicopathological parameters

From: GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

  Total patients GP96 over-expression  
    No Yes  
  No. % No. % No. % P
Gender        0.518*
   Male 77 97.5 23 30 54 70  
   Female 2 2.5 1 50 1 50  
Age (years)        0.573
   ≤ 48 44 51 11 27.5 29 72.5  
   > 48 39 49 13 33 26 67  
Smoking        0.573*
   No 14 18 4 29 10 71  
   Yes 65 82 20 31 45 69  
Drinking        0.237
   No 19 24 4 21 15 79  
   Yes 60 76 20 33 40 67  
Betel-quid chewing        0.427*
   No 14 18 5 36 9 64  
   Yes 65 82 19 29 46 71  
Stage        0.349*
   I-II 13 16.5 5 38.5 8 61.5  
   III-IV 66 83.5 19 29 47 71  
T stage        0.390
   T1-2 36 46 12 33 24 67  
   T3-4 43 54 12 28 31 72  
Nodal stage        0.020
   N0-1 44 56 18 41 26 59  
   N2 35 44 6 17 29 83  
Nodal ECS        0.183
   No 45 57 16 33 29 67  
   Yes 34 43 8 23.5 26 76.5  
Differentiation        0.654
   Well 24 30 9 37.5 15 62.5  
   Moderate 47 60 13 28 34 72  
   Poor 8 10 2 25 6 75  
Depth (millimeters)        0.045
   ≤10 30 38 13 43 17 57  
   > 10 49 62 11 22 38 78  
Skin invasion        0.641*
   No 72 91 22 31 50 69  
   Yes 7 9 2 29 5 71  
Bone invasion        0.402
   No 56 71 18 32 38 68  
   Yes 23 29 6 26 17 74  
Perineural invasion        0.424
   No 53 67 15 28 38 72  
   Yes 24 30 8 33 16 67  
   Missing 2 3      
Blood Vessel invasion        
   No 72 91 22 31 50 69 0.528*
   Yes 5 6 1 20 4 80  
   Missing 2 3      
Lymphatic vessel invasion        0.069*
   No 65 82 22 34 43 66  
   Yes 12 15 1 8 11 92  
   Missing 2 3      
Margin status (millimeters)        0.605*
   ≥ 5 66 83.5 20 30 46 70  
   < 5 13 16.5 4 31 9 69  
  1. * Fisher's exact test
  2. Abbreviations: ECS = extracapsular spreading